Drug Profile


Alternative Names: Avishot; BM 15275; Eapidil; Flivas; KT 611; Naphtopidil

Latest Information Update: 22 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Asahi Kasei; Asahi Kasei Pharma Corp; Dong-A ST; MSD KK
  • Class Antihypertensives; Naphthalenes; Piperazines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Benign prostatic hyperplasia
  • Phase III Postoperative pain; Urinary calculi
  • No development reported Neurogenic bladder

Most Recent Events

  • 01 Aug 2015 Dong-A ST completes a phase III trial in Urinary calculi in South Korea (NCT01952314)
  • 01 May 2014 Phase-III clinical trials in Urinary calculi in South Korea (PO) (NCT01952314)
  • 10 Dec 2013 Samsung Medical Center plans a phase III trial for Ureteral calculi in South Korea (NCT02011737)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top